Clinical efficacy of tolvaptan in acute decompensated heart failure patients with severe aortic stenosis and atrial fibrillation: a sub-analysis from the LOHAS registry

Tsutomu Murakami,Yusuke Watanabe,Norihito Nakamura,Makoto Natsumeda,Yohei Ohno,Gaku Nakazawa,Yuji Ikari,Akihisa Kataoka,Yosuke Nishihata,Kentaro Hayashida,Masanori Yamamoto,Jun Tanaka,Kentaro Jujo,Masaki Izumo,Kazuki Mizutani,Ken Kozuma
DOI: https://doi.org/10.1007/s00380-024-02397-3
2024-05-08
Heart and Vessels
Abstract:Severe aortic valve stenosis (AS) and atrial fibrillation (AF) are risk factors of hemodynamic instability in heart failure (HF) management due to low cardiac output, respectively. Therefore, the treatment of HF due to severe AS complicated with AF is anticipated to be difficult. Tolvaptan, a vasopressin V2 receptor inhibitor, is effective in controlling acute decompensated heart failure (ADHF) with hemodynamic stability. However, its clinical efficacy against ADHF caused by AS with AF remains to be determined.
cardiac & cardiovascular systems,peripheral vascular disease
What problem does this paper attempt to address?